IGFBP-1 combined with CHRDL1 in mid-pregnancy serum for predicting fetal growth restriction in late pregnancy among women with gestational hypertension: a prospective nested case-control study

Haiying Diao; Wei Chen; Wei Zhang

doi:10.1080/14767058.2026.2680353

June 7, 2026The Journal of Maternal-Fetal & Neonatal MedicineOpen Access

IGFBP-1 combined with CHRDL1 in mid-pregnancy serum for predicting fetal growth restriction in late pregnancy among women with gestational hypertension: a prospective nested case-control study

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study aims to explore the relationship between mid-pregnancy serum levels of IGFBP-1 and CHRDL1 and the risk of fetal growth restriction in women with gestational hypertension.
Conducted within a cohort of pregnant women with gestational hypertension from 2021 to 2025.
731 singleton women enrolled, with 318 participants in the final sample assessed for fetal growth restriction based on ultrasound.
Serum levels of IGFBP-1 and CHRDL1 measured by ELISA; data analyzed using conditional logistic regression and ROC curve analysis.
Elevated levels of IGFBP-1 and CHRDL1 associated with increased fetal growth restriction risk (AUC 0.801 for combined prediction).
Independent risk factors for FGR included elevated systolic and diastolic blood pressure, IGFBP-1, and CHRDL1; triglycerides were protective.
The predictive ability of IGFBP-1 and CHRDL1: IGFBP-1 AUC = 0.734, CHRDL1 AUC = 0.704.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Prospective nested case-control study investigates early serum biomarkers for predicting fetal growth restriction in women with gestational hypertension, highlighting their clinical relevance.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Diao et al. (2026) studied this question.

synapsesocial.com/papers/6a28fe326f82f25be989ba0f https://doi.org/10.1080/14767058.2026.2680353

View Full Paper

Ask AI

Bookmark

Share

IGFBP-1 combined with CHRDL1 in mid-pregnancy serum for predicting fetal growth restriction in late pregnancy among women with gestational hypertension: a prospective nested case-control study

Key Points

No abstract yet

Implication

Discussion

Cite This Study

IGFBP-1 combined with CHRDL1 in mid-pregnancy serum for predicting fetal growth restriction in late pregnancy among women with gestational hypertension: a prospective nested case-control study

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading